These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Fraticelli P; Gabrielli B; Pomponio G; Valentini G; Bosello S; Riboldi P; Gerosa M; Faggioli P; Giacomelli R; Del Papa N; Gerli R; Lunardi C; Bombardieri S; Malorni W; Corvetta A; Moroncini G; Gabrielli A; Arthritis Res Ther; 2014 Jul; 16(4):R144. PubMed ID: 25007944 [TBL] [Abstract][Full Text] [Related]
33. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492 [TBL] [Abstract][Full Text] [Related]
34. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287 [TBL] [Abstract][Full Text] [Related]
35. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. Takahashi T; Asano Y; Akamata K; Aozasa N; Taniguchi T; Noda S; Masui Y; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S Mod Rheumatol; 2013 Sep; 23(5):884-90. PubMed ID: 22972016 [TBL] [Abstract][Full Text] [Related]
36. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Liu X; Mayes MD; Pedroza C; Draeger HT; Gonzalez EB; Harper BE; Reveille JD; Assassi S Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1375-80. PubMed ID: 23401350 [TBL] [Abstract][Full Text] [Related]
37. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. Furuya Y; Kuwana M J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489 [TBL] [Abstract][Full Text] [Related]
38. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. Yilmaz N; Can M; Kocakaya D; Karakurt S; Yavuz S Int J Rheum Dis; 2014 Nov; 17(8):923-8. PubMed ID: 24864029 [TBL] [Abstract][Full Text] [Related]
39. Serum S100A12 levels: Possible association with skin sclerosis and interstitial lung disease in systemic sclerosis. Omatsu J; Saigusa R; Miyagawa T; Fukui Y; Toyama S; Awaji K; Ikawa T; Norimatsu Y; Yoshizaki A; Sato S; Asano Y Exp Dermatol; 2021 Mar; 30(3):409-415. PubMed ID: 33068321 [TBL] [Abstract][Full Text] [Related]
40. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O; Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]